Literature DB >> 8170192

Cigarette smoking and ulcerative colitis: a case-control study.

M D Silverstein1, B A Lashner, S B Hanauer.   

Abstract

OBJECTIVE: To determine whether the previously reported decreased risk of ulcerative colitis in current smokers and increased risk in former smokers are explained by age, sex, race, ethnicity, or socioeconomic status.
DESIGN: We conducted a case-control study at a university hospital gastroenterology clinic.
MATERIAL AND METHODS: One hundred patients with ulcerative colitis and 100 age- and sex-matched community control subjects were randomly selected for a telephone interview to collect information on smoking habits, race, religion, income, education, and occupation. Smoking habits at the onset of symptoms were analyzed with use of conditional logistic regression for matched data to obtain adjusted odds ratios and 95% confidence intervals for current or former smokers.
RESULTS: In comparison with those who had never smoked, current smokers were less likely to have ulcerative colitis: odds ratio = 0.13; 95% confidence interval = 0.05 to 0.38. Former smokers had no increased risk for ulcerative colitis: odds ratio = 1.24; 95% confidence interval = 0.52 to 2.95. No dose-response effect was noted on the basis of pack-years of cigarette smoking, and among former smokers, the interval since quitting smoking was not significantly associated with the relative risk of ulcerative colitis. No confounding effect was detected from race, religion, income, education, or occupation.
CONCLUSION: An association seems to exist between ulcerative colitis and nonsmoking; perhaps patients with ulcerative colitis who smoke are less likely to experience symptoms than are nonsmokers because of the effects of nicotine.

Entities:  

Mesh:

Year:  1994        PMID: 8170192     DOI: 10.1016/s0025-6196(12)61637-1

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  9 in total

1.  Immunosuppressive and anti-inflammatory effects of nicotine administered by patch in an animal model.

Authors:  Roma Kalra; Shashi P Singh; Juan C Pena-Philippides; Raymond J Langley; Seddigheh Razani-Boroujerdi; Mohan L Sopori
Journal:  Clin Diagn Lab Immunol       Date:  2004-05

2.  Smoking and inflammatory bowel diseases: what in smoking alters the course?

Authors:  A M El-Tawil
Journal:  Int J Colorectal Dis       Date:  2010-03-24       Impact factor: 2.571

Review 3.  Epidemiology and clinical characteristics of sarcoidosis: an update from a population-based cohort study from Olmsted County, Minnesota.

Authors:  P Ungprasert; C S Crowson; E L Matteson
Journal:  Reumatismo       Date:  2017-05-22

4.  Cigarette smoking, appendectomy, and tonsillectomy as risk factors for the development of primary sclerosing cholangitis: a case control study.

Authors:  S A Mitchell; M Thyssen; T R Orchard; D P Jewell; K A Fleming; R W Chapman
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

Review 5.  Epidemiological studies of migration and environmental risk factors in the inflammatory bowel diseases.

Authors:  Yanna Ko; Rhys Butcher; Rupert W Leong
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

6.  Passive smoking and inflammatory bowel disease: a meta-analysis.

Authors:  Deborah T Jones; Mark T Osterman; Meenakshi Bewtra; James D Lewis
Journal:  Am J Gastroenterol       Date:  2008-09       Impact factor: 10.864

Review 7.  Pulmonary-intestinal cross-talk in mucosal inflammatory disease.

Authors:  S Keely; N J Talley; P M Hansbro
Journal:  Mucosal Immunol       Date:  2011-11-16       Impact factor: 7.313

8.  Assessing health-related quality of life in patients with inflammatory bowel disease, in Crete, Greece.

Authors:  Athanasios G Pallis; Ioannis G Vlachonikolis; Ioannis A Mouzas
Journal:  BMC Gastroenterol       Date:  2002-01-10       Impact factor: 3.067

9.  Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: Preliminary results from a randomized trial.

Authors:  Sunanda Kane; William Holderman; Peter Jacques; Todd Miodek
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.